BAYESGENRX · GENERIC DEVELOPMENT

Develop generics with evidence you can trace.

Connect reference-product science, formulation, virtual bioequivalence and quality with evidence requirements for the US, EU and India.

Explore scientific requirements Book a walkthrough

Designed for pharmaceutical development teams. Scientific and regulatory decisions remain with qualified reviewers.

GLOBAL REGULATORY SCIENTIFIC INTELLIGENCE

One programme. Market-specific evidence.

Compare scientific development questions across FDA, European and Indian requirements. Product-specific applicability and regulatory acceptance still require qualified review.

Open scientific requirements Open Programme Control ↗
UNITED STATES · FDAReference listed drug, product-specific guidance and ANDA evidence.Explore US requirements EUROPEAN UNIONReference medicinal products, applicable EMA guidance and CMC evidence.Explore EU requirements INDIA · CDSCOComparator strategy, applicable standards, BA/BE and manufacturing evidence.Explore India requirements

Read-only public exploration. Controlled programme evidence is assessed within the authenticated workbench. A status or reference is not an agency approval.

A CONNECTED SCIENTIFIC WORKFLOW

Find the right workspace for your next decision.

Choose the scientific question you want to investigate next.

01Reference-product intelligenceReference evidence, hypotheses and reverse engineeringExplore → 02GenRx Virtual BEModel-informed product performance and BE hypothesesExplore → 03Global Regulatory ScienceFDA, EU and India evidence requirementsExplore → 04BayesPeaQ QualityGoverned QMS records, CAPA and reviewer decisionsExplore → 05Programme ControlProduct revisions, evidence lineage and accountable reviewExplore →
Evidence-first pharmaceutical QMS

Quality you can operate.
Evidence you can defend.

Connect investigations, CAPA, signatures and controlled evidence to accountable quality reviews. AI surfaces gaps; authorized quality personnel review, decide and sign.

Explore BayesPeaQ Open quality workspace

Evaluate BayesPeaQ independently or as part of your GenRx programme. Its controls are designed around ISO/IEC 27001:2022-aligned security practices, 21 CFR Part 11 electronic-record expectations and EU GMP Annex 11 principles. Standards-aligned design is not certification; suitability depends on intended use, configuration, qualification and validation.

Quality case · GX-SAMPLE-01Illustrative sample data
Evidence review open

Investigate the development evidence gap.

  1. Event reportedDissolution evidence needs a method-context review.
  2. Evidence linkedCandidate comparison r1 and analytical observations.
  3. Investigation in reviewQA assesses the rationale and missing evidence.

Illustrative workflow preview. Authorized quality personnel retain the decision.

Capability directory

Find the workspace
for your next question.

Search the complete scientific module catalogue. Access remains subject to product and account permissions.

Featured capabilities
Before your walkthrough

Practical questions.
Clear answers.

Start with the development question your team owns.

Who is BayesGenRx for?

Formulation, analytical, biopharmaceutics, MSAT, quality, regulatory and programme teams working on generic development and lifecycle evidence.

Can we evaluate BayesPeaQ independently?

Yes. BayesPeaQ can be evaluated as an evidence-first pharmaceutical QMS on its own, or the relevant governed quality workflows can be included in a GenRx walkthrough.

What will the walkthrough show?

A focused product workflow, its inputs, representative evidence outputs, unresolved questions and accountable review steps. Choose the area that matters to your team.

Do we need to provide confidential product data?

You can start with the public sample and a general development question. Discuss any product-data requirements and handling arrangements before sharing sensitive evidence.

Which decisions remain with our team?

Model applicability, scientific interpretation, quality decisions, regulatory strategy and submission authorization remain with qualified and authorized reviewers.

How do MIDD and Route Extrapolation relate to GenRx?

GenRx includes model-informed and virtual BE workflows. MIDD Command Center and Route Extrapolation Studio are related BayesARC workspaces. Review access, evidence scope and the specific programme handoff during your evaluation.

Which integrations can we evaluate?

Discuss the specific workspace, source system and handoff your programme needs. The public sample illustrates workflow relationships; it does not demonstrate every external integration.

A focused product walkthrough

See BayesGenRx with your team’s development question.

Choose a reference-product question, formulation challenge, evidence gap or target market. We will focus the walkthrough on one scientific decision your team owns.

Start with your development question Labeled sample data before sensitive data Clear success criteria and review boundary